Harnessing genomic profiling for improved urothelial cancer outcomes.
1/5 보강
[INTRODUCTION] Genomic profiling has revolutionized the management of Urothelial carcinomas (UC), particularly in muscle-invasive bladder cancer (MIBC) and metastatic UC, by identifying molecular subt
APA
Yu EM, Linville L, et al. (2026). Harnessing genomic profiling for improved urothelial cancer outcomes.. Expert review of anticancer therapy, 26(1), 93-104. https://doi.org/10.1080/14737140.2025.2575827
MLA
Yu EM, et al.. "Harnessing genomic profiling for improved urothelial cancer outcomes.." Expert review of anticancer therapy, vol. 26, no. 1, 2026, pp. 93-104.
PMID
41090689 ↗
Abstract 한글 요약
[INTRODUCTION] Genomic profiling has revolutionized the management of Urothelial carcinomas (UC), particularly in muscle-invasive bladder cancer (MIBC) and metastatic UC, by identifying molecular subtypes and actionable mutations that guide personalized therapies and prognostication.
[AREAS COVERED] The integration of genomic profiling in UC, potential prognostic and predictive biomarkers of prognosis, and the current landscape of systemic therapies in UC, including FGFR inhibitors (FGFRi), antibody-drug conjugates (ADC), immune checkpoint inhibitors (ICI), and chemotherapy are discussed herein as a narrative and descriptive review.
[EXPERT OPINION] Genomic profiling has advanced our understanding of UC diagnosis and treatment, but its routine clinical use remains limited to confirming biomarkers such as FGFR alterations and HER2 amplification for approved targeted therapies such as erdafitinib, a FGFRi, and trastuzumab deruxtecan, a HER2-directed ADC. Testing for other biomarkers such as PD-L1, tumor mutational burden (TMB), and Nectin-4 can be useful, but not required for the use of ICI and enfortumab vedotin. Circulating tumor DNA (ctDNA) is an emerging tool for monitoring disease and guiding therapy, with trials underway to confirm its clinical utility.
[AREAS COVERED] The integration of genomic profiling in UC, potential prognostic and predictive biomarkers of prognosis, and the current landscape of systemic therapies in UC, including FGFR inhibitors (FGFRi), antibody-drug conjugates (ADC), immune checkpoint inhibitors (ICI), and chemotherapy are discussed herein as a narrative and descriptive review.
[EXPERT OPINION] Genomic profiling has advanced our understanding of UC diagnosis and treatment, but its routine clinical use remains limited to confirming biomarkers such as FGFR alterations and HER2 amplification for approved targeted therapies such as erdafitinib, a FGFRi, and trastuzumab deruxtecan, a HER2-directed ADC. Testing for other biomarkers such as PD-L1, tumor mutational burden (TMB), and Nectin-4 can be useful, but not required for the use of ICI and enfortumab vedotin. Circulating tumor DNA (ctDNA) is an emerging tool for monitoring disease and guiding therapy, with trials underway to confirm its clinical utility.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Biomarkers
- Tumor
- Urinary Bladder Neoplasms
- Precision Medicine
- Molecular Targeted Therapy
- Prognosis
- Carcinoma
- Transitional Cell
- Mutation
- Circulating Tumor DNA
- Genomics
- Immune Checkpoint Inhibitors
- Antineoplastic Agents
- Animals
- Urothelial cancer
- genomic expression profiling
- immunotherapy
- molecular subtype
- upper tract urothelial cancer
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.